This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Atlanthera. Active years: 2015-2019.
Company Filing History:
Years Active: 2015-2019
Title: The Innovative Contributions of Ronan Le Bot
Introduction
Ronan Le Bot is a notable inventor based in Nantes, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug compounds. With a total of 2 patents to his name, Le Bot's work focuses on enhancing the efficacy of treatments for serious medical conditions.
Latest Patents
One of Le Bot's latest patents is for hydrosoluble hydroxybisphosphonic derivatives of doxorubicin. This invention relates to hydrosoluble compounds that can be used as drugs, especially in the treatment of bone tumors. The patent also covers the pharmaceutical compositions that include these compounds, as well as methods for their synthesis and the synthesis intermediates involved.
Another significant patent by Le Bot is for bifunctional hydroxy-bisphosphonic acid derivatives. This invention includes a method for producing these derivatives, pharmaceutical compositions containing them, and their use as medicaments. Additionally, it discusses a compound that can be utilized for creating vectorized molecules for therapeutic or diagnostic purposes.
Career Highlights
Ronan Le Bot is currently associated with Atlanthera, a company focused on innovative pharmaceutical solutions. His work at Atlanthera has allowed him to explore new avenues in drug development and contribute to advancements in medical treatments.
Collaborations
Le Bot has collaborated with several professionals in his field, including Maxim Egorov and Jean-Yves Goujon. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.
Conclusion
Ronan Le Bot's contributions to the pharmaceutical industry through his patents and collaborative efforts highlight his commitment to advancing medical science. His innovative work continues to pave the way for new treatments that can significantly impact patient care.